西妥昔单抗联合FOLFIRI治疗晚期结肠癌的不良反应及耐受性分析被引量：2

导出

摘要目的研究分析采用西妥昔单抗联合FOLFIRI化疗治疗晚期结肠癌的疗效。方法选取2012-012014-08河南省中医院收治的晚期结肠癌患者184例作为研究对象，随机分为对照组和观察组。对照组92例患者给予FOLFIRI方案化疗，观察组92例患者则在此基础上联合西妥昔单抗进行治疗。对两组的疗效及不良反应进行观察分析和对比。结果治疗后统计分析显示，对照组完全缓解4例，部分缓解24例，进展34例，稳定30例，疾病控制率（DCR）为63．04％，客观缓解率（RR）为30．43％；观察组完全缓解8例，部分缓解40例，进展12例，稳定32例，DCR为86．96％，RR为52．17％。从两组患者的DCR和RR比较看来，疗效差异有统计学意义，P〈0．05。在不良反应的发生方面，两组在恶心呕吐、肝功能损害及骨髓抑制、神经毒性发生率的比较方面差异无统计学意义；在皮疹发生率方面，对照组为26．09％，观察组为67．39％，P〈0．01。结论在对晚期结肠癌患者的治疗中，相比于单纯FOLFIRI方案化疗，其联合西妥昔单抗的治疗效果更好，且其带来的不良反应可以耐受，应当推荐使用。

作者王玉萍

机构地区河南省中医院肿一病区

出处《中华肿瘤防治杂志》 CAS 北大核心 2015年第B11期137-138,共2页 Chinese Journal of Cancer Prevention and Treatment

关键词结肠肿瘤 FOLFIRI化疗西妥昔单抗耐受性

分类号 R735.35 [医药卫生—肿瘤]

引文网络
相关文献

参考文献3

1王晓红,黄颖.比较单用FOLFIRI化疗方案及其与西妥昔单抗联用治疗晚期结肠癌的疗效[J].中国临床药理学杂志,2011,27(12):972-975. 被引量：15
2茅慧,石燕,王治宽,吴志勇,戴广海.西妥昔单抗联合FOLFIRI与单用FOLFIRI方案治疗转移性结直肠癌近期疗效的对照研究[J].现代生物医学进展,2012,12(10):1893-1896. 被引量：8
3曾进龙,王志超,张海良,李志花.FOLFIRI化疗方案及其与西妥昔单抗联用治疗晚期结肠癌分析[J].临床医学工程,2012,19(11):1929-1930. 被引量：11

二级参考文献32

1Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor [J]. Clin Cancer Res,2005; 11 : 397 -405.
2Ng M, Cunningham D. Cetuximab (Erbium) - an emerging targeted therapy for epidermalgrowth factor receptor - expressing tumors [ J ]. In J Clin Pract ,2004; 58: 970- 976.
3Cunningham D, Humblet Y, Siena S, et al. Cetuximab mono -therapy and cetuximab plus irinotecan in irinoteean refractory metastatic colorectal cancer [ J ]. N Engl J Med,2004 ; 351:337 - 345.
4Tsuchihashi Z, Khambata - Ford S, Hanna N, et al. Responsiveness to cetuximab without mutations in EGFR[J]. N Engl J Med,2005; 353 : 208 - 209.
5Skvortsov S, Sarg B, Loeffler - RaggJ, et al. Different proteome pattern of epidermal growth factor receptor - positive colorectal cancer cell lines that are responsive and nonresponsive to cetuximab antibody treatment[ J]. Mol Cancer Ther,2004 ; 3 : 1551 - 1558.
6Folprecht G, Lutz MP, Schiffski P, et al. Cetuximab and irinotecan/ 5 - fluorouraeil/folinic acid is a safe combination for the first - line treatment of patients frith epidermal growth factor receptor expressing metastatic coloreetal carcinoma [ J ]. Ann Oncol, 2006 ; 17 : 450 - 456.
7Berge E, Thompson C, Messersmith W. Development of novel targeted agents in the treatment of metastatic colorectal cancer [J].Clin Colorectal Cancer, 2011, 10(4): 266-278.
8Van Cutsem E. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial[J]. J Clin Oncol(Meeting Abstracts), 2007, 25(18): 4000-4003.
9Garci a FJ, DJ az RE. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome [J]. Clin Transl Oncol, 2010, 12(8): 533-542.
10Porschen R, Arkenau HT, Kubicka S, et al. Phase IlI study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer:a final report of the AIO Colorectal Study Group [J]. J Clin Oncol, 2007, 25 (27): 4217-23.